Barclays PLC Boosts Stock Position in ICU Medical, Inc. (NASDAQ:ICUI)

Barclays PLC increased its position in ICU Medical, Inc. (NASDAQ:ICUI) by 15.6% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 59,207 shares of the medical instruments supplier’s stock after acquiring an additional 8,010 shares during the quarter. Barclays PLC’s holdings in ICU Medical were worth $10,790,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Innealta Capital LLC bought a new position in shares of ICU Medical in the second quarter worth approximately $32,000. Hexagon Capital Partners LLC boosted its holdings in ICU Medical by 162.7% in the 3rd quarter. Hexagon Capital Partners LLC now owns 197 shares of the medical instruments supplier’s stock worth $36,000 after buying an additional 122 shares during the period. Allworth Financial LP boosted its holdings in ICU Medical by 100.0% in the 3rd quarter. Allworth Financial LP now owns 200 shares of the medical instruments supplier’s stock worth $36,000 after buying an additional 100 shares during the period. Venturi Wealth Management LLC increased its stake in ICU Medical by 1,510.0% in the 3rd quarter. Venturi Wealth Management LLC now owns 322 shares of the medical instruments supplier’s stock worth $59,000 after buying an additional 302 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in ICU Medical during the second quarter valued at about $70,000. Institutional investors own 96.10% of the company’s stock.

Insider Activity at ICU Medical

In other news, CEO Vivek Jain sold 12,000 shares of the business’s stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $171.84, for a total transaction of $2,062,080.00. Following the transaction, the chief executive officer now owns 104,593 shares of the company’s stock, valued at approximately $17,973,261.12. The trade was a 10.29 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director David C. Greenberg sold 972 shares of the firm’s stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $158.11, for a total value of $153,682.92. Following the completion of the sale, the director now owns 5,037 shares of the company’s stock, valued at approximately $796,400.07. This represents a 16.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 40,364 shares of company stock valued at $6,869,878 over the last 90 days. 6.70% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on ICUI. KeyCorp increased their target price on ICU Medical from $198.00 to $209.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 13th. Raymond James increased their price objective on shares of ICU Medical from $158.00 to $190.00 and gave the company an “outperform” rating in a report on Thursday, September 12th. Needham & Company LLC reissued a “hold” rating on shares of ICU Medical in a report on Wednesday, November 13th. StockNews.com raised shares of ICU Medical from a “hold” rating to a “buy” rating in a research note on Wednesday, November 20th. Finally, Jefferies Financial Group upgraded shares of ICU Medical from a “hold” rating to a “buy” rating and set a $200.00 price target on the stock in a research note on Wednesday, December 11th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $199.67.

ICU Medical Stock Down 1.6 %

Shares of ICUI opened at $159.06 on Tuesday. The business’s 50 day simple moving average is $170.76 and its 200-day simple moving average is $152.04. ICU Medical, Inc. has a 1 year low of $86.80 and a 1 year high of $196.26. The company has a debt-to-equity ratio of 0.75, a current ratio of 2.29 and a quick ratio of 1.03. The stock has a market capitalization of $3.89 billion, a price-to-earnings ratio of -34.81 and a beta of 0.62.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.